Topics:

Melanoma

History of Prostate Cancer Linked With Risk for Melanoma

Men with a history of prostate cancer may be at increased risk for melanoma, according to data taken from two large cohort studies.

Melanoma

Combined treatment of BRAFV600-mutated melanoma with the MEK inhibitor cobimetinib and the BRAF inhibitor vemurafenib was safe and tolerable, according to the results of a phase Ib study.

Dr. Atkins offers his perspective on the “race” between the top two anti-PD1 drugs (Merck’s MK-3475 and Bristol-Myers Squibb’s nivolumab), and weighs in on where thew new agent pidilizumab fits into the picture.

The presence of regression in melanomas with a Breslow thickness greater than 0.75 mm does not appear to be linked to a higher likelihood of sentinel node involvement, according to the results of a retrospective study.

Long-term results from a phase I study demonstrate that concurrent treatment with ipilimumab and nivolumab led to an unprecedented improvement in survival for patients with advanced melanoma.

The story of how the targeted therapies, immunotherapies, and combinations of these therapies have been developed for use in patients with advanced melanoma holds a number of important lessons for the development of agents for use in other tumor types.

On Monday during ASCO, Dr. Axel Hauschild reviewed the role of intralesional therapy in melanoma in a sub-session of the melanoma abstract review talk entitled “Evolving Utility of Intralesional Therapy for Melanoma.”

The results of a prospective study showed that the risk of developing melanoma is higher for white women with a history of strong sun exposure during childhood and adolescence, rather than adulthood.

Pages

Subscribe to Melanoma on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.